Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Unicycive Therapeutics Inc (UNCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/26/2025: UNCY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.09% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 64.23M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 962053 | Beta 2.25 | 52 Weeks Range 0.20 - 1.60 | Updated Date 03/27/2025 |
52 Weeks Range 0.20 - 1.60 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.85% | Return on Equity (TTM) -147.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 32689216 | Price to Sales(TTM) 62.82 |
Enterprise Value 32689216 | Price to Sales(TTM) 62.82 | ||
Enterprise Value to Revenue 16.63 | Enterprise Value to EBITDA -1.03 | Shares Outstanding 103796000 | Shares Floating 54692402 |
Shares Outstanding 103796000 | Shares Floating 54692402 | ||
Percent Insiders 6.12 | Percent Institutions 60.39 |
Analyst Ratings
Rating 4.5 | Target Price 5.5 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Unicycive Therapeutics Inc
Company Overview
History and Background
Unicycive Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for kidney diseases. Founded in 2017, the company is dedicated to addressing unmet needs in the treatment of acute kidney injury and chronic kidney diseases.
Core Business Areas
- Renal Disease Therapies: Unicycive is focused on developing and commercializing therapies for kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD).
Leadership and Structure
Peter A. Bierbaum is the current Chief Executive Officer. The company operates with a structure typical of a small biopharmaceutical company, with departments focused on research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- RenalGuard System: RenalGuard System, designed to reduce Acute Kidney Injury (AKI) following cardiac surgery. They are developing for post-operative AKI prevention but do not yet have substantial market share or revenue as of the last update. Competitors include companies offering similar preventative measures such as contrast-induced nephropathy prevention strategies.
- Losartan nanoparticle: Losartan nanoparticle which is for the treatment of chronic kidney disease. This product is in the clinical trial stage. The market share is zero since the product has not been commercialized yet. Competitors include companies offering ACE inhibitors and ARBs for CKD.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. The market for kidney disease therapies is growing due to the increasing prevalence of diabetes and hypertension, major risk factors for kidney disease.
Positioning
Unicycive is a small player in the renal disease therapeutics market, focusing on innovative therapies for AKI and CKD. The company is positioned as a developer of novel treatments with a goal of addressing unmet medical needs.
Total Addressable Market (TAM)
The global kidney disease market is estimated to be in the tens of billions of dollars. Unicycive is focused on capturing a portion of this market with its innovative therapies. Losartan, for example, has a total addressable market in the multiple billions.
Upturn SWOT Analysis
Strengths
- Focus on a significant unmet medical need (kidney disease)
- Innovative technology platform
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Lack of established commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas within kidney disease
- Favorable regulatory environment for innovative therapies
Threats
- Competition from established pharmaceutical companies
- Failure to obtain regulatory approval
- Adverse clinical trial results
Competitors and Market Share
Key Competitors
- VTVT
- AKBA
- KALA
Competitive Landscape
Unicycive faces competition from established players with greater resources. Their advantage lies in their focus on innovative therapies and addressing specific unmet needs in kidney disease.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and financial milestones.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for their lead compounds and exploring strategic partnerships.
Summary
Unicycive Therapeutics is a development-stage biopharmaceutical company with a focus on kidney diseases. Its strength lies in its innovative approach and focus on unmet medical needs, but weaknesses include limited resources and dependence on clinical trial outcomes. The company needs to successfully navigate regulatory hurdles and clinical trials. It has the potential to make a mark in the kidney disease therapeutics market.
Similar Companies
- VTVT
- AKBA
- KALA
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (10-K, 10-Q)
- Analyst reports
- Press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Unicycive Therapeutics Inc
Exchange NASDAQ | Headquaters Los Altos, CA, United States | ||
IPO Launch date 2021-07-12 | Founder, Chairman, CEO & President Dr. Shalabh K. Gupta M.D., MPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://unicycive.com |
Full time employees 14 | Website https://unicycive.com | ||
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.